- Home
- SJW vs APGE Comparison
SJW vs APGE Comparison
Compare SJW & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJW
- APGE
- Stock Information
- Founded
- SJW 1866
- APGE 2022
- Country
- SJW United States
- APGE United States
- Employees
- SJW N/A
- APGE N/A
- Industry
- SJW Water Supply
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SJW Utilities
- APGE Health Care
- Exchange
- SJW Nasdaq
- APGE Nasdaq
- Market Cap
- SJW 1.9B
- APGE 2.1B
- IPO Year
- SJW N/A
- APGE 2023
- Fundamental
- Price
- SJW $54.37
- APGE $37.05
- Analyst Decision
- SJW Strong Buy
- APGE Strong Buy
- Analyst Count
- SJW 3
- APGE 4
- Target Price
- SJW $57.00
- APGE $91.33
- AVG Volume (30 Days)
- SJW 305.2K
- APGE 745.7K
- Earning Date
- SJW 04-28-2025
- APGE 05-12-2025
- Dividend Yield
- SJW 3.10%
- APGE N/A
- EPS Growth
- SJW 7.09
- APGE N/A
- EPS
- SJW 2.87
- APGE N/A
- Revenue
- SJW $748,439,000.00
- APGE N/A
- Revenue This Year
- SJW $2.55
- APGE N/A
- Revenue Next Year
- SJW $3.99
- APGE $743.14
- P/E Ratio
- SJW $18.91
- APGE N/A
- Revenue Growth
- SJW 11.65
- APGE N/A
- 52 Week Low
- SJW $44.91
- APGE $26.20
- 52 Week High
- SJW $62.18
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- SJW 53.94
- APGE 55.84
- Support Level
- SJW $53.79
- APGE $31.38
- Resistance Level
- SJW $55.54
- APGE $38.75
- Average True Range (ATR)
- SJW 1.86
- APGE 3.03
- MACD
- SJW 0.15
- APGE 0.56
- Stochastic Oscillator
- SJW 75.57
- APGE 86.45
About SJW SJW Group (DE)
SJW Group is a U.S. water utility services holding company that provides, stores, purifies and distributes water. The company predominantly operates in various Californian municipalities and also has operations in other states. Its operating segments include Water Utility Services and Real Estate Services. The majority of the company's revenue is derived from its water utility services segment.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.